74 results about "Chronic leukemia" patented technology

Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

The invention discloses an STAT (Signal Transducer And Activator Of Transcription)3 signal channel small-molecule inhibitor and application thereof. The inhibitor is expressed in a chemical structural formula which is shown in the specification, wherein R1 is halogenated aryl, R2 is halogenated aryl, R3 is oxygen or sulphur. The inhibitor has functions of effectively inhibiting the multiplication of various tumor cells and inducing the apoptosis of the various tumor cells. The newly developed STAT3 signal channel small-molecule inhibitor not only has a remarkable inhibition effect on the phosphorylation of the STAT3, but also has the remarkable inhibition effect on the IL-6-induced STAT3 activation and the activation of the STAT3 upstream signal CrC and Jak2, and therefore, the multiplication of the various tumor cells can be inhibited and the apoptosis of tumor cells can be induced. Besides, the STAT3 signal channel small-molecule inhibitor has an in-vitro and vivo treatment effect on various tumors of acute and chronic leukemia, multiple myeloma, lymphoma, lung cancer, prostate cancer, cervical cancer and the like.

The invention discloses a pharmaceutical composition for treating leukemia or aplastic anemia, and the pharmaceutical composition comprises American ginseng, Chinese caterpillar fungus, dragon's blood, pangolin scales, musk, bezoar, pearl, Hawksbill Carapace, palourde powder, prepared nux vomica, toad venom, toad skin and the like. The pharmaceutical composition is mainly used for treating various types of acute and chronic leukemia, aplastic anemia and thrombocytopenia. The pharmaceutical composition has the effects of clearing heat-toxin, promoting blood circulation, removing blood stasis, stopping bleeding, promoting production of blood and activating hematopoietic function. Furthermore, the pharmaceutical composition has the advantages of convenient administration, easy absorption, rapid onset of action, good effect, low cost, no toxicity or side effects and the like.

The invention discloses a traditional Chinese medicine combination for treating leukemia and a preparation method thereof. The combination is prepared by realgar, indigo naturalis, salvia miltiorrhiza and borneol according to a certain weight proportioning. The combination can be prepared into any kind of usual dosage form. The traditional Chinese medicine combination of the invention has the functions of clearing heat, detoxicating and invigorating blood circulation and is applied to treating various chronic and acute leukemias.

The invention discloses an indolocarbazole compounds as well as a preparation method and application of indolocarbazole. The compound is of a structure shown in a formula I, a formula II and formula III as shown in the description. The compound provided by the invention can be used for treating acute leukemia, chronic leukemia, lymphoma, breast cancer, lung cancer, stomach cancer and other cancers related to inhibition of protein kinase, and can be applied to a drug for treating diseases such as Aids, coronary heart disease, diabetes mellitus and senile dementia. The invention also discloses a preparation method of a compound for resisting tumors, the compound for resisting tumors is prepared by fermenting with a marine-derived actinomycetes rice solid culture medium, and separating and purifying a yeast obtained after extraction of ethyl acetate by adopting gel column chromatography and high performance liquid chromatography, and the operation is easy to operate and implement.

The invention discloses compounds with anti-tumor activity as well as a preparation method and an application of the compounds. The structures of the compounds are shown as formulae (I) and (II) in the description. The compounds can be used for preparing drugs for treating diseases such as acute leukemia and chronic leukemia associated with protein kinase inhibition, lymphoma, breast cancer, lung cancer and other cancer, acquired immune deficiency syndrome, coronary heart disease, diabetes mellitus, senile dementia and the like. The invention further provides the preparation method of the compounds with the anti-tumor activity. According to the preparation method, marine actinomycete is fermented with a rice solid medium, a fermentation product obtained after extraction with ethyl acetate is subjected to separation and purification with gel column chromatography and preparative liquid chromatography, and the method is easy to operate and implement.

The invention relates to a traditional Chinese medicine for treating leukemia. The traditional Chinese medicine comprises the components as follows: 150-170 g of buffalo horns, 150-170 g of indigo naturalis, 150-170 g of moutan bark, 110-130 g of scutellaria baicalensis, 150-170 g of oldenlandia diffusa, 150-170 g of astragalus membranaceus, 58-62 g of coptis chinensis, 78-82 g of rehmannia and 18-22 g of American ginseng. A formula of the traditional Chinese medicine also can comprise the components as follows: 10-15 g of honeysuckles, 15-30 g of houttuynia cordata, 6-12 g of cacumen biotae and 3-15 g of folium artemisiae argyi. All the components are combined, functions of benefiting qi and nourishing blood, detoxifying and clearing marrow, cooling and activating blood and enabling juvenile cells to be subjected to differentiation and apoptosis are realized. The traditional Chinese medicine is used for treating poison stasis incubation, a qi-blood deficiency syndrome and various types of acute and chronic leukemia. By means of clinical application for many years, the effect is clear, and the toxic and side effects are small.

The invention discloses a preparation method of fructus gleditsiae total saponins. The preparation method is characterized by comprising the following steps of: (1) taking a dried fructus gleditsiae medical material, and grinding the medical material into coarse powder; (2) taking the fructus gleditsiae coarse powder, adding deionized water, decocting and filtering out, extracting for three times, combining filtrate, and carrying vacuum concentration to obtain liquid medicine; (3) taking the liquid medicine, extracting with a water saturated n-butyl alcohol solution for 3 times, combining n-butyl alcohol extracting solutions, reducing pressure and recovering to obtain an n-butyl alcohol extract; and (4) taking the n-butyl alcohol extract, adding water for dissolution, filtering out, collecting filtrate, adding into a D101 macroporous resin column, firstly eluting with distilled water till the filtrate is near colorless, then eluting with 10% ethanol till the filtrate is near colorless, finally eluting with 70% ethanol, collecting 70% ethanol eluant, and drying under reduced pressure to obtain the fructus gleditsiae total saponins. The fructus gleditsiae total saponins obtained by the method is light brown orange powder, acrid and salty in taste and has pungent smell of saponin; the content of the total saponins is above 80%; and the fructus gleditsiae total saponins can be used for treating acute and chronic leukemia.

The invention relates to a new use of isorhodanic ester compound in preparing pharmaceuticals for treatment of leukemia. The isorhodanic ester compound in preparing pharmaceuticals for treatment of leukemia has strong pharmacological action as well as characteristics of broad spectrum, special effect and low toxicity, thereby having good medical prospect. Additionally, the invention can be used for acute leukemia (including acute myelaid leukemia, acute T lymphatic leukemia and acute promyelocytic leukemia, and the like) and chronic leukemia.

A pimarane type diterpenoid compound having an oxygen-containing five-membered ring is disclosed. The chemical structure of the compound is shown as a formula (I) in the description. In-vitro activitytests prove that the compound has high inhibitory activity for a plurality of human tumor cells such as human pancreatic cancer cells PANC-1, human breast carcinoma cells MCF-7, human colon cancer cells HCT-116, human chronic leukemia cells K562 and human pancreatic cancer cells SW1990, and can be used for preparing antitumor medicines.

The invention provides a water-soluble monodemethoxycurcumin derivative as shown in general formula I and a pharmaceutically acceptable salt thereof. The compound has higher water solubility as well as high antitumor activity, has a function of inhibiting human gastric carcinoma cells MGC-803, human hepatocellular carcinoma cells Bel-7402, human chronic leukemia granulocytes K562 and human glioma U87 to different extents, and can be used for preparing an antitumor medicament, and the IC50 (Inhibitory Concentration 50) reaches the level of 1 [mu]M.

The invention discloses a Staurosporine aldehyde substituted derivative as well as a preparation method and application thereof. The compound, namely the Staurosporine aldehyde substituted derivative, has structures represented by a formula I and a formula II. The compound provided by the invention can be used for treating cancers such as acute and chronic leukemia, lymph cancer, breast cancer, lung cancer as well as diseases such as AIDS, coronary heart disease, diabetes mellitus and senile dementia which are relevant with protein kinase inhibition. The preparation method comprises the steps of carrying out fermentation by virtue of a marine actinomycete rice solid culture medium, carrying out extraction by virtue of ethyl acetate, carrying out gel column chromatography and high performance liquid chromatography and separation on the obtained ferment, so as to obtain the Staurosporine aldehyde substituted derivative. The preparation method is easy in operation and implementation.

A new herbal-based composition and method for treatment of CD33+ acute and chronic myeloid leukemia by Piper betel leaf extracts, and to provide a process for the isolation of active fractions from leaves or any other plant parts of Piper betel to treat CD3 3+ AML and CML with a simplified method of isolation of active components from all plant parts of Piper betel possessing biological activities relevant to the treatment of CD33+ AML and CML.

The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumours, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne.

A method is provided for treating a patient afflicted with a hematologic disorder such as chronic leukemia and the myelodysplastic syndromes. The method includes administering to the patient an effective amount of a water-insoluble 20(S)-camptothecin compound with a closed lactone ring, a derivative thereof, or a mixture thereof. In a preferred method, the compound administered is 9-nitro-20(S)-camptothecin. The compound can be administered orally, intramuscularly, transdermally, subcutaneously, or parenterally.

The invention discloses a traditional Chinese medicine combination for treating leukemia and a preparation method thereof. The combination is prepared by realgar, indigo naturalis, angelica and ligusticum wallichii according to a certain weight proportioning. The combination can be prepared into any kind of usual dosage form. The traditional Chinese medicine combination of the invention has the functions of clearing heat, detoxicating and invigorating blood circulation and is applied to treating various chronic and acute leukemias.

The invention discloses a traditional Chinese medicine for treating leukemia. The traditional Chinese medicine is prepared from the following raw materials in percentage by weight: 12-18 parts of root of rehmannia, 15-25 parts of selfheal, 30-40 parts of oldenlandia diffusa, 12-20 parts of root bark of peony tree, 50-60 parts of cornu bubali, 40-50 parts of radix scrophulariae, 30-40 parts of radix isatidis, 5-12 parts of gardenia, 8-15 parts of codonopsis pilosula, 4-10 parts of rhizoma polygonati and 10-20 parts of fructus psoraleae. The traditional Chinese medicine for treating leukemia takes the cornu bubali and the radix scrophulariae as main medicines and is combined with other adjuvants, and the main medicines and the adjuvants act with each other to take a synergistic effect, so as to take excellent effects of clearing away heat and toxic materials, tonifying qi and yin, promoting blood circulation and removing stasis; the traditional Chinese medicine has good treating effect on leukemia, in particular chronic leukemia; and the traditional Chinese medicine is relatively simple in raw material, safe and free from side effect, and convenient to take.

The invention discloses a traditional Chinese medicine composition for treating leukemia. The composition comprises the following raw medicines by weight: 3-10 grams of cephalotaxus fortune, 3-10 grams of camptotheca acuminate, 3-10 grams of catharanthus roseus, 9-20 grams of indigo naturalis, 9-20 grams of folium isatidis, 3-10 grams of diversifolious patrinia root, 5-20 grams of common threewingnut root, 3-10 grams of galium aparine, 5-20 grams of calculus bovis, 3-10 grams of vietnamese sophora root, 9-20 grams of lithospermum and 9-20 grams of rumex japonicus root. The composition has the beneficial effects that the indigo naturalis and the calculus bovis mainly have the effects of clearing heat and removing toxicity; the medicines are combined and jointly have the effects of benefiting qi and nourishing blood, removing toxicity and clearing marrow, cooling blood and activating blood to promote differentiation and apoptosis of juvenile cells. The composition is used for treating the symptoms such as fever, heat, headache, bone pain, anemia, hemorrhage, palpitation, lack of strength, tinnitus, soreness and weakness of waists and knees, lumps in the abdomen, scrofula, subcutaneous nodule, petechiae on the tongue, greasy fur tongue, slippery pulse or wiry pulse and the like caused by various acute and chronic leukemia with internal toxicity stasis and qi-blood deficiency.

The present invention provides a compound as represented by formula I, pharmaceutically acceptable salt, preparation method, use and pharmaceutical composition thereof. The compound represented by formula I is as follows:_(Formula I).The compound as represented by formula I has more excellent anti-cancer or anti-tumor effect, can inhibit various kinases inside cell and on cell surface simultaneously, and therefore has more efficient anti-cancer or anti-tumor effect, the kinases comprising PI3-K kinase and mTOR kinase. The pharmaceutical composition provided in the present invention can be used for treating cerebral cancer, glioblastoma, cervicocerebral cancer, lung cancer, melanoma, liver cancer, renal cancer, acute leukemia, chronic leukemia、non-small cell lung cancer、prostate cancer, thyroid cancer, skin cancer, colon cancer, rectal cancer, pancreatic cancer, ovarian cancer, breast cancer, myelodysplasia syndromes, esophageal cancer, sarcoma, osteosarcoma and rhabdomyoma.